X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GSK

GSK expands Exdensur approval in China to CRSwNP

The NMPA has approved Exdensur for adults with chronic rhinosinusitis with nasal polyps, based on phase III data showing improved nasal polyp and obstruction scores, with tolerability similar to placebo...
Brava Health

Brava Health expands clinical intelligence within its operating system

Brava Health is expanding its operating system with integrated pain validation and chronic care tools, aiming to give clinicians better context and more timely insight before appointments begin...
Brava Health

Brava Health expands EMR Platform with new pain validation and chronic care integration

Brava Health announced the integration of a proprietary pain validation and chronic care methodology, developed by Johns Hopkins alumni and professors, into its EMR platform to support earlier diagnostics, longitudinal..
Brava Health

Why operating room efficiency is becoming a strategic investment priority

Hospitals can create more surgical capacity by fixing workflow problems rather than simply arguing over theatre time...
intravenous (IV) line

AstraZeneca reports positive Phase III EMERALD-3 results in unresectable liver cancer

In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular carcinoma, with an interim..
CIZ

Cizzle Biotechnology secures up to £250,000 funding facility to support CIZ1B test launch

Cizzle Biotechnology has entered into a new unsecured convertible loan note facility with existing investor Frazer Lang, giving the company access to up to £250,000 to support the planned commercial..
NFX

Dr Dan Gooding on Nuformix’s NXP002 opportunity in idiopathic pulmonary fibrosis

Executive Director Dr Dan Gooding discusses Nuformix’s NXP002 programme for idiopathic pulmonary fibrosis, the value of FDA orphan drug designation, and how the recent fundraise supports partnering discussions...
BIOG

Biotech Growth Trust portfolio company Apellis to be acquired by Biogen

Biotech Growth Trust notes Biogen’s agreement to acquire portfolio company Apellis Pharmaceuticals for approximately $5.6 billion, with potential additional milestone-based payments...
Aptamer Group

Aptamer Group retail offer raises £274,000, total fundraise reaches £4.5 million

Aptamer Group said its retail offer closed having raised about £274,000 before expenses. Subject to shareholder approval at the general meeting on 13 April 2026, the company expects to issue..
ETHY

Ethtry appoints founder Mike Murphy as executive director

Ethtry Plc has appointed founder Mike Murphy to the board as an executive director with immediate effect. The company said Murphy’s capital markets experience and knowledge of the business will..
GSK

GSK wins China approval for Exdensur in severe asthma

GSK said China’s National Medical Products Administration approved Exdensur (depemokimab) for severe eosinophilic asthma in adults and adolescents aged 12 and older, supported by phase III data showing sustained exacerbation..
CVS Group plc

CVS Group CEO Richard Fairman to retire following successor appointment

CVS Group plc has announced that Chief Executive Officer Richard Fairman intends to retire from the Board and his role for personal reasons. He will remain in post until a..
Verici Dx Plc

Verici Dx expands its route to market through Illinois coverage agreement

Verici Dx has improved access for Tutivia in Illinois and strengthened its positioning for broader US payer expansion...
GSK

GSK advances bepirovirsen in Europe with EMA review acceptance

The EMA has accepted GSK’s application for bepirovirsen in chronic hepatitis B, following Phase III data showing statistically significant functional cure rates versus standard of care alone...
Aptamer

Aptamer Group launches retail offer to raise up to £0.5 million at 0.6p per share

Aptamer Group plc has opened a UK retail offer through the BookBuild Platform to raise up to £0.5 million by issuing up to 83.3 million new ordinary shares at 0.6..
Brava Health

Patient-controlled data could become healthcare’s next strategic battleground

Patient ownership of health data could become a defining issue in healthcare, with major implications for AI adoption, platform strategy and where long-term sector value is created...
Aptamer Group

Aptamer Group reports higher H1 revenue and launches £3.75m bookbuild

Aptamer Group said H1 2026 revenue rose 27% to £0.83 million, with progress across licensing, fee-for-service contracts and asset development. The company also announced a bookbuild expected to raise at..
EDX

EDX Medical to lead Scottish Prostate Cancer Testing Initiative

EDX Medical will serve as the primary delivery partner for the Scottish Prostate Cancer Initiative, which plans to offer free PSA testing to 25,000 men across Scotland and explore ways..
Brava Health

Brava Health and the investment case for time-centred care

Brava Health is building a time-centred health and wellness proposition that focuses on better living, clearer outcomes and stronger long-term relevance...
GENF

Genflow Biosciences Secures £800k Funding and €4m Grant to Advance Gene Therapy Programme

Genflow Biosciences (LON:GENF) has secured fresh funding and grant support to accelerate its gene therapy research, highlighting growing momentum in the longevity biotech space. With a blend of equity financing..

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

GSK

GSK expands Exdensur approval in China to CRSwNP

The NMPA has approved Exdensur for adults with chronic rhinosinusitis with nasal polyps, based on phase III data showing improved nasal polyp and obstruction scores, with tolerability similar to placebo...
Brava Health

Brava Health expands clinical intelligence within its operating system

Brava Health is expanding its operating system with integrated pain validation and chronic care tools, aiming to give clinicians better context and more timely insight before appointments begin...
Brava Health

Brava Health expands EMR Platform with new pain validation and chronic care integration

Brava Health announced the integration of a proprietary pain validation and chronic care methodology, developed by Johns Hopkins alumni and professors, into its EMR platform to support earlier diagnostics, longitudinal monitoring, and more informed clinical decision-making...
Brava Health

Why operating room efficiency is becoming a strategic investment priority

Hospitals can create more surgical capacity by fixing workflow problems rather than simply arguing over theatre time...
intravenous (IV) line

AstraZeneca reports positive Phase III EMERALD-3 results in unresectable liver cancer

In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular carcinoma, with an interim trend toward overall survival benefit...
CIZ

Cizzle Biotechnology secures up to £250,000 funding facility to support CIZ1B test launch

Cizzle Biotechnology has entered into a new unsecured convertible loan note facility with existing investor Frazer Lang, giving the company access to up to £250,000 to support the planned commercial launch of its CIZ1B biomarker test in North America, expansion in the UK and Europe, and ongoing clinical work with Moffitt Cancer Center...
NFX

Dr Dan Gooding on Nuformix’s NXP002 opportunity in idiopathic pulmonary fibrosis

Executive Director Dr Dan Gooding discusses Nuformix’s NXP002 programme for idiopathic pulmonary fibrosis, the value of FDA orphan drug designation, and how the recent fundraise supports partnering discussions...
BIOG

Biotech Growth Trust portfolio company Apellis to be acquired by Biogen

Biotech Growth Trust notes Biogen’s agreement to acquire portfolio company Apellis Pharmaceuticals for approximately $5.6 billion, with potential additional milestone-based payments...
Aptamer Group

Aptamer Group retail offer raises £274,000, total fundraise reaches £4.5 million

Aptamer Group said its retail offer closed having raised about £274,000 before expenses. Subject to shareholder approval at the general meeting on 13 April 2026, the company expects to issue 45.7 million shares at 0.6p each, bringing total gross proceeds from the placing, subscription and retail offer to about £4.5 million...
ETHY

Ethtry appoints founder Mike Murphy as executive director

Ethtry Plc has appointed founder Mike Murphy to the board as an executive director with immediate effect. The company said Murphy’s capital markets experience and knowledge of the business will support its growth and Ethereum-focused treasury strategy...
GSK

GSK wins China approval for Exdensur in severe asthma

GSK said China’s National Medical Products Administration approved Exdensur (depemokimab) for severe eosinophilic asthma in adults and adolescents aged 12 and older, supported by phase III data showing sustained exacerbation reduction versus placebo...
CVS Group plc

CVS Group CEO Richard Fairman to retire following successor appointment

CVS Group plc has announced that Chief Executive Officer Richard Fairman intends to retire from the Board and his role for personal reasons. He will remain in post until a successor is appointed to support an orderly transition...
Verici Dx Plc

Verici Dx expands its route to market through Illinois coverage agreement

Verici Dx has improved access for Tutivia in Illinois and strengthened its positioning for broader US payer expansion...
GSK

GSK advances bepirovirsen in Europe with EMA review acceptance

The EMA has accepted GSK’s application for bepirovirsen in chronic hepatitis B, following Phase III data showing statistically significant functional cure rates versus standard of care alone...
Aptamer

Aptamer Group launches retail offer to raise up to £0.5 million at 0.6p per share

Aptamer Group plc has opened a UK retail offer through the BookBuild Platform to raise up to £0.5 million by issuing up to 83.3 million new ordinary shares at 0.6 pence each, with one warrant for every three shares subscribed...
Brava Health

Patient-controlled data could become healthcare’s next strategic battleground

Patient ownership of health data could become a defining issue in healthcare, with major implications for AI adoption, platform strategy and where long-term sector value is created...
Aptamer Group

Aptamer Group reports higher H1 revenue and launches £3.75m bookbuild

Aptamer Group said H1 2026 revenue rose 27% to £0.83 million, with progress across licensing, fee-for-service contracts and asset development. The company also announced a bookbuild expected to raise at least £3.75 million to extend cash runway into 2028...
EDX

EDX Medical to lead Scottish Prostate Cancer Testing Initiative

EDX Medical will serve as the primary delivery partner for the Scottish Prostate Cancer Initiative, which plans to offer free PSA testing to 25,000 men across Scotland and explore ways to improve early detection and diagnosis of the disease...
Brava Health

Brava Health and the investment case for time-centred care

Brava Health is building a time-centred health and wellness proposition that focuses on better living, clearer outcomes and stronger long-term relevance...
GENF

Genflow Biosciences Secures £800k Funding and €4m Grant to Advance Gene Therapy Programme

Genflow Biosciences (LON:GENF) has secured fresh funding and grant support to accelerate its gene therapy research, highlighting growing momentum in the longevity biotech space. With a blend of equity financing and non-dilutive backing, the company is advancing its mission to tackle age-related diseases at the genetic level...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple